Sprout Pharmaceuticals, Valeant Pharmaceuticals deal

Valeant will acquire Sprout for $1 billion in cash. Last week, FDA approved Addyi flibanserin, a serotonin (5-HT1A) receptor agonist and 5-HT2A receptor antagonist, from Sprout to treat acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. The approval includes a REMS requiring prescriber and pharmacist certification. Addyi, which Valeant expects to launch in 4Q15, will have a boxed warning noting risks of severe hypotension and syncope in patients who drink alcohol, use moderate or strong cytochrome P450 3A4 (CYP3A4) inhibitors or have liver impairment. ...